Click to cell type (#count): Fibroblast (6972) Epithelial cell (1095) Stromal cell (33) Fetal stromal cell (42) Smooth muscle cell (32) Macrophage (1288) Erythroid cell (44)
Tissue and cell type-associated traits map for all cell types in [Placenta] . Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-05 as default, and users can change it to 1e-04, 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple trait-associated-gene (TAG) sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below. Users could further select to only show the association for those ‘tissue-specfic cell types’ defined from ontology analysis.
Table. List of Tissue-cell type associated traits pairs for [Placenta]. If the network above is too complicated, the users could obtain the association information from the table at bottom. Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Cell type | Trait name | Trait full name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|---|
Epithelial cell | 2 Hour Glucose | 2-Hour Glucose | ETC | Saxena | 2010 | NA | 15234 | 1.00e-2 | 2.78e-2 |
Smooth muscle cell | ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 3.95e-2 |
Epithelial cell | ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 2.81e-2 |
Erythroid cell | Age At Death | Age At Death | MTC | Pilling | 2016 | NA | 45627 | 5.00e-2 | 1.68e-2 |
Fetal stromal cell | Age At Death | Age At Death | MTC | Pilling | 2016 | NA | 45627 | 1.00e-2 | 1.71e-2 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 2.51e-5 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 2.61e-5 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 2.17e-5 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 4.35e-8 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 5.05e-8 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 5.00e-2 | 8.25e-5 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-2 | 1.77e-4 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-3 | 1.34e-4 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-4 | 2.94e-5 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 4.45e-4 |
Erythroid cell | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-2 | 3.76e-2 |
Epithelial cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 1.67e-2 |
Epithelial cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-2 | 2.82e-2 |
Epithelial cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-3 | 1.83e-2 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 5.72e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-2 | 1.72e-4 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-3 | 3.29e-6 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 7.76e-5 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 2.95e-4 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 7.43e-3 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 1.34e-3 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 3.44e-4 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 2.38e-5 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 8.73e-5 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 5.00e-2 | 1.71e-3 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-2 | 1.46e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 1.01e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 4.42e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-5 | 1.55e-2 |
Fibroblast | BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-4 | 2.13e-2 |
Fibroblast | Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 1.00e-2 | 7.53e-3 |
Erythroid cell | Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 1.00e-2 | 2.37e-2 |
Erythroid cell | Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 5.00e-2 | 1.79e-2 |
Erythroid cell | Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-5 | 2.88e-2 |
Fibroblast | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-3 | 3.76e-2 |
Stromal cell | BMI | Body Mass Index | MTC | Wood | 2016 | 29925 | 89763 | 5.00e-2 | 4.78e-2 |
Fetal stromal cell | BMI | Body Mass Index | MTC | Wood | 2016 | 29925 | 89763 | 5.00e-2 | 4.67e-3 |
Macrophage | BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-3 | 3.86e-2 |
Macrophage | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 2.81e-2 |
Fetal stromal cell | Breast Cancer | Breast Cancer | MTC | Hunter | 2007 | NA | 1145 | 5.00e-2 | 2.40e-2 |
Macrophage | Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 1.01e-3 |
Macrophage | Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 1.00e-2 | 3.78e-2 |
Macrophage | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 3.81e-2 |
Macrophage | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 3.98e-2 |
Fetal stromal cell | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 2.09e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 3.82e-2 |
Macrophage | CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-3 | 1.12e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 1.03e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 4.87e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-4 | 3.71e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-5 | 4.16e-2 |
Fibroblast | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 1.07e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 4.22e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 1.75e-2 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 5.00e-2 | 9.35e-4 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 8.58e-5 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 3.11e-3 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 1.48e-3 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 1.09e-2 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 5.00e-2 | 5.08e-4 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-2 | 2.88e-3 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-3 | 9.39e-4 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-4 | 2.54e-3 |
Erythroid cell | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-3 | 1.03e-2 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 2.60e-2 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-2 | 3.64e-3 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-3 | 1.31e-2 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 3.60e-3 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 2.13e-4 |
Smooth muscle cell | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.51e-3 |
Fetal stromal cell | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 6.03e-3 |
Smooth muscle cell | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 1.51e-3 |
Fetal stromal cell | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 6.03e-3 |
Fetal stromal cell | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-5 | 3.75e-2 |
Fibroblast | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 6.69e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 2.14e-2 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 4.15e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-4 | 3.53e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-5 | 7.40e-4 |
Stromal cell | Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 5.00e-2 | 3.92e-2 |
Stromal cell | Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-2 | 2.12e-2 |
Smooth muscle cell | Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 5.00e-2 | 2.68e-2 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 8.81e-5 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 1.77e-6 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 1.15e-9 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 5.32e-11 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 1.18e-11 |
Smooth muscle cell | Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 1.07e-2 |
Fetal stromal cell | Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 5.00e-2 | 4.30e-2 |
Stromal cell | Obesity Childhood | Obesity Childhood | MTC | Bradfield | 2012 | 5530 | 8318 | 1.00e-4 | 1.77e-2 |
Fibroblast | Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 1.00e-3 | 4.42e-2 |
Smooth muscle cell | Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 5.00e-2 | 4.66e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 5.00e-2 | 2.19e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 1.18e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-3 | 3.19e-3 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 1.77e-3 |
Epithelial cell | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 2.16e-2 |
Epithelial cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 1.71e-2 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 1.24e-5 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 4.22e-7 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 3.79e-9 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 1.38e-10 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 6.93e-10 |
Epithelial cell | Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 5.00e-2 | 4.59e-2 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 3.86e-2 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 9.66e-3 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 2.74e-3 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 8.95e-4 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 1.01e-4 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 4.37e-6 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 1.90e-6 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 1.28e-3 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 1.24e-5 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 2.18e-12 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 7.24e-13 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 4.47e-13 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 4.71e-3 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-4 | 1.14e-3 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 3.62e-3 |
Macrophage | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 5.00e-2 | 3.51e-2 |
Macrophage | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-3 | 4.80e-2 |
Epithelial cell | Sleep Duration | Sleep Duration | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-2 | 4.38e-2 |
Macrophage | Sleep Duration | Sleep Duration | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-2 | 4.38e-2 |
Erythroid cell | Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 5.00e-2 | 3.89e-2 |
Erythroid cell | Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-2 | 1.36e-2 |
Epithelial cell | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 6.93e-3 |
Epithelial cell | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 3.24e-2 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 5.00e-2 | 3.08e-2 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-2 | 4.06e-2 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-3 | 4.17e-2 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes | MTC | Wood | 2016 | 4040 | 113735 | 1.00e-2 | 2.70e-2 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 8.75e-5 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 6.26e-6 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 5.68e-7 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 7.92e-10 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 1.11e-8 |
Fetal stromal cell | Visual Refractive Error | Visual Refractive Error | MTC | Stambolian | 2013 | NA | 7280 | 5.00e-2 | 3.18e-2 |
Epithelial cell | Visual Refractive Error | Visual Refractive Error | MTC | Stambolian | 2013 | NA | 7280 | 1.00e-2 | 1.71e-2 |
Macrophage | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-2 | 1.24e-2 |
Macrophage | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-4 | 4.35e-2 |
Fibroblast | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-3 | 3.42e-2 |
Macrophage | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-3 | 3.42e-2 |
Macrophage | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-4 | 4.51e-3 |
Macrophage | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-5 | 1.16e-2 |
Macrophage | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 5.00e-2 | 5.28e-3 |
Macrophage | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 1.00e-2 | 9.02e-3 |
Smooth muscle cell | Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 4.35e-2 |
Stromal cell | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 2.57e-2 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 2.57e-2 |
Epithelial cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 7.85e-5 |
Stromal cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 3.21e-2 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 3.21e-2 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 2.29e-2 |
Stromal cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-2 | 4.46e-2 |
Fetal stromal cell | Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-2 | 4.16e-2 |
Stromal cell | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 4.44e-2 |
Smooth muscle cell | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 5.55e-3 |
Epithelial cell | Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-5 | 3.62e-2 |
Fetal stromal cell | Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 5.00e-2 | 4.20e-2 |
Fetal stromal cell | Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 1.00e-3 | 2.09e-2 |
Epithelial cell | Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-2 | 2.92e-2 |
Epithelial cell | Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 3.62e-2 |
Epithelial cell | Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-3 | 3.78e-2 |
Macrophage | Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 5.00e-2 | 3.64e-2 |
Fibroblast | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-2 | 5.37e-3 |
Fibroblast | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 8.31e-3 |
Stromal cell | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 8.31e-3 |
Fibroblast | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 2.44e-2 |
Fetal stromal cell | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-3 | 4.89e-2 |
Epithelial cell | Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 3.90e-2 |
Macrophage | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 2.07e-2 |
Stromal cell | Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 5.00e-2 | 4.09e-2 |
Erythroid cell | Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 5.00e-2 | 4.93e-2 |
Fibroblast | Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 2.00e-2 |
Macrophage | Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 5.00e-2 | 3.40e-2 |
Fibroblast | Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-3 | 4.89e-2 |
Epithelial cell | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 3.86e-2 |
Epithelial cell | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 3.09e-2 |
Epithelial cell | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-3 | 9.42e-3 |
Smooth muscle cell | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 1.67e-2 |
Epithelial cell | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 4.89e-2 |
Epithelial cell | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-4 | 3.44e-2 |
Epithelial cell | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-5 | 5.16e-3 |
Fetal stromal cell | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 4.89e-2 |
Macrophage | Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.83e-2 |
Smooth muscle cell | Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.35e-2 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 9.37e-5 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 6.93e-6 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.35e-4 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 1.01e-4 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-5 | 2.54e-3 |
Erythroid cell | Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.52e-2 |
Macrophage | Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.26e-2 |
Erythroid cell | Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.49e-5 |
Erythroid cell | Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.45e-2 |
Macrophage | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.00e-2 |
Macrophage | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 6.52e-3 |
Macrophage | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.48e-4 |
Macrophage | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.13e-2 |
Erythroid cell | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.44e-2 |
Macrophage | Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 8.97e-3 |
Smooth muscle cell | Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 9.42e-3 |
Macrophage | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.08e-3 |
Macrophage | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 7.57e-5 |
Macrophage | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.64e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 5.00e-2 | 4.70e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-2 | 5.40e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-3 | 5.93e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-5 | 2.79e-2 |
Fetal stromal cell | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 3.21e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 8.95e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 3.54e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 1.86e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-4 | 7.26e-4 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-5 | 2.08e-3 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 5.00e-2 | 1.36e-3 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-2 | 1.71e-4 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 1.15e-4 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 1.00e-4 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-5 | 3.76e-6 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 5.00e-2 | 1.86e-4 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-2 | 1.22e-5 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-3 | 7.82e-4 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-4 | 1.13e-4 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-5 | 6.25e-4 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 8.58e-4 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 2.55e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 1.23e-4 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.03e-4 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 2.87e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 5.96e-4 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.25e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 1.36e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 8.11e-5 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 2.73e-4 |
Fetal stromal cell | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.95e-2 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 2.75e-5 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.85e-5 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 7.15e-5 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.45e-5 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 2.87e-7 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.72e-4 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 4.50e-6 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 4.43e-5 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.69e-4 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 4.37e-5 |
Stromal cell | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 5.00e-2 | 2.47e-2 |
Stromal cell | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 1.00e-2 | 6.25e-4 |
Fetal stromal cell | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 5.00e-2 | 2.10e-2 |
Fetal stromal cell | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-2 | 1.45e-2 |
Epithelial cell | BMI Physical Activity Interaction | BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 3.74e-2 |
Stromal cell | BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.01e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.40e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 5.00e-3 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.63e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.28e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.72e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.30e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 2.02e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.97e-3 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.28e-3 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.69e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.99e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.37e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.69e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.99e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 1.67e-2 |
Epithelial cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 2.13e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 5.08e-3 |
Erythroid cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.59e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.14e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 3.49e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.18e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.51e-3 |
Epithelial cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.48e-2 |
Smooth muscle cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.37e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 3.21e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.21e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 5.85e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.72e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 5.94e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 6.55e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 5.88e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.32e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.02e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 7.56e-3 |
Erythroid cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.75e-2 |
Fetal stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.76e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.96e-2 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 8.68e-3 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.14e-2 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.38e-2 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 3.60e-3 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 5.76e-3 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 5.67e-3 |
Fibroblast | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.30e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.40e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.02e-3 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 6.52e-3 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 7.54e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.18e-4 |
Smooth muscle cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.44e-2 |
Fibroblast | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 2.94e-2 |
Fibroblast | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.05e-2 |
Stromal cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.14e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.77e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.68e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 4.42e-3 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.01e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 8.17e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 7.06e-3 |
Epithelial cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 4.42e-2 |
Epithelial cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-4 | 9.60e-3 |
Erythroid cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-2 | 6.74e-3 |
Epithelial cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-5 | 2.96e-2 |
Fibroblast | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 1.00e-2 | 2.22e-2 |
Fibroblast | Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 5.00e-2 | 2.15e-2 |
Epithelial cell | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 5.00e-2 | 4.09e-3 |
Epithelial cell | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 2.28e-2 |
Erythroid cell | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 1.27e-3 |
Smooth muscle cell | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 2.06e-2 |
Smooth muscle cell | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 4.99e-2 |
Macrophage | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-2 | 1.39e-2 |
Macrophage | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-3 | 1.89e-2 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 4.72e-2 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 1.05e-2 |
Macrophage | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-4 | 2.42e-2 |
Macrophage | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-5 | 3.55e-2 |
Fetal stromal cell | Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 5.00e-2 | 4.19e-2 |
Stromal cell | Diarrhoeal Disease | Diarrhea Age 2 | MTC | Bustamante | 2016 | 2855 | 2753 | 5.00e-2 | 9.31e-3 |
Epithelial cell | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 5.00e-2 | 3.67e-2 |
Epithelial cell | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-2 | 1.34e-2 |
Fetal stromal cell | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 5.00e-2 | 2.01e-2 |
Epithelial cell | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 2.34e-2 |
Macrophage | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 3.38e-2 |
Macrophage | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 1.50e-2 |
Macrophage | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-3 | 4.77e-2 |
Fibroblast | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 2.70e-2 |
Fibroblast | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-3 | 1.16e-2 |
Macrophage | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-3 | 3.74e-2 |
Fetal stromal cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 1.38e-2 |
Fetal stromal cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 4.61e-2 |
Macrophage | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 3.02e-2 |
Fetal stromal cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 1.00e-3 | 1.37e-2 |
Fibroblast | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 4.25e-2 |
Fibroblast | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 4.79e-2 |
Fetal stromal cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 1.28e-2 |
Fetal stromal cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 6.35e-3 |
Macrophage | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 2.84e-2 |
Macrophage | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-2 | 8.18e-3 |
Fibroblast | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation All | MTC | Chu | 2017 | NA | 11478 | 1.00e-3 | 2.93e-2 |
Stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 4.35e-2 |
Fibroblast | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-2 | 3.99e-2 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-2 | 1.14e-2 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 4.31e-2 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 4.28e-3 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 8.75e-5 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-4 | 3.98e-3 |
Smooth muscle cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 2.04e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 5.62e-3 |
Fibroblast | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 2.86e-2 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 3.58e-2 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 1.09e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 1.16e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 3.85e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 2.41e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 1.56e-3 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 1.56e-3 |
Fetal stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 9.42e-3 |
Smooth muscle cell | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 1.23e-2 |
Smooth muscle cell | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 1.23e-2 |
Smooth muscle cell | Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.18e-2 |
Smooth muscle cell | Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.00e-4 |
Smooth muscle cell | Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 2.51e-3 |
Smooth muscle cell | Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 3.68e-3 |
Smooth muscle cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 2.23e-2 |
Smooth muscle cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 3.50e-2 |
Smooth muscle cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-3 | 4.05e-2 |
Smooth muscle cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-4 | 4.89e-2 |
Macrophage | Estimated Glomerular Filtration Rate | Serum Creatinine African Americans Only | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 4.62e-2 |
Fibroblast | Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.39e-3 |
Fetal stromal cell | Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.87e-3 |
Fetal stromal cell | Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 8.79e-3 |
Fibroblast | Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.73e-4 |
Fibroblast | Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.55e-2 |
Macrophage | Facial Shape | Mod14 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.21e-2 |
Macrophage | Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.23e-3 |
Stromal cell | Facial Shape | Mod16 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.73e-3 |
Stromal cell | Facial Shape | Mod16 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.33e-2 |
Macrophage | Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 8.43e-3 |
Stromal cell | Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.46e-3 |
Stromal cell | Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.86e-2 |
Fibroblast | Facial Shape | Mod20 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.28e-2 |
Fetal stromal cell | Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.96e-2 |
Stromal cell | Facial Shape | Mod22 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.57e-2 |
Stromal cell | Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.49e-3 |
Fetal stromal cell | Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.36e-2 |
Stromal cell | Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.57e-3 |
Stromal cell | Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.11e-2 |
Fibroblast | Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.45e-2 |
Fibroblast | Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.66e-4 |
Macrophage | Facial Shape | Mod29 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.88e-2 |
Stromal cell | Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.03e-2 |
Fetal stromal cell | Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.39e-2 |
Epithelial cell | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.99e-2 |
Fibroblast | Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.38e-3 |
Fibroblast | Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.43e-2 |
Stromal cell | Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.35e-2 |
Stromal cell | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.32e-2 |
Epithelial cell | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.96e-2 |
Stromal cell | Facial Shape | Mod42 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.92e-2 |
Stromal cell | Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.35e-2 |
Stromal cell | Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.54e-4 |
Fibroblast | Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.54e-3 |
Fibroblast | Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.71e-2 |
Stromal cell | Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.24e-2 |
Stromal cell | Facial Shape | Mod53 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.77e-2 |
Fibroblast | Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.55e-2 |
Erythroid cell | Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.72e-2 |
Macrophage | Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.88e-2 |
Fibroblast | Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.17e-2 |
Fetal stromal cell | Facial Shape | Mod6 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.86e-2 |
Epithelial cell | Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.13e-2 |
Smooth muscle cell | Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 7.09e-3 |
Fetal stromal cell | Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.28e-2 |
Smooth muscle cell | Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.28e-2 |
Fetal stromal cell | Facial Shape | Mod63 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.63e-4 |
Fetal stromal cell | Facial Shape | Mod63 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.46e-3 |
Macrophage | Facial Shape | Mod7 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.88e-3 |
Fetal stromal cell | Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.57e-2 |
Fetal stromal cell | Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.77e-2 |
Fetal stromal cell | Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-4 | 2.48e-2 |
Smooth muscle cell | Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-4 | 4.78e-2 |
Stromal cell | Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 4.62e-2 |
Smooth muscle cell | Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-3 | 2.51e-2 |
Fetal stromal cell | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 2.23e-2 |
Smooth muscle cell | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 3.26e-2 |
Macrophage | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 6.27e-3 |
Macrophage | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 1.00e-2 | 3.33e-2 |
Smooth muscle cell | Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 1.45e-2 |
Erythroid cell | Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-3 | 1.03e-3 |
Macrophage | Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.65e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.39e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.99e-3 |
Fibroblast | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.73e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 4.35e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 2.09e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.17e-2 |
Stromal cell | Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.67e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.26e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.38e-2 |
Stromal cell | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 9.93e-3 |
Erythroid cell | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 4.35e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 2.45e-2 |
Erythroid cell | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.33e-2 |
Fibroblast | Glycemic Traits BMI Corrected | Fasting Glucose | MTC | Manning | 2012 | NA | 58074 | 1.00e-3 | 2.21e-2 |
Macrophage | Glycemic Traits BMI Corrected | Fasting Insulin | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 4.58e-2 |
Epithelial cell | Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 4.22e-2 |
Fetal stromal cell | Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 1.00e-3 | 3.39e-2 |
Fibroblast | Glycemic Traits | Fasting Glucose | ETC | Dupuis | 2010 | NA | 46186 | 1.00e-5 | 1.55e-2 |
Erythroid cell | Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-4 | 4.35e-2 |
Macrophage | Glycemic Traits | HOMA IR | MTC | Dupuis | 2010 | NA | 37037 | 5.00e-2 | 4.83e-2 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 1.97e-2 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 1.14e-2 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 2.08e-2 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 7.20e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 7.13e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 1.24e-4 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 9.02e-5 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 1.25e-4 |
Fibroblast | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 1.23e-2 |
Fibroblast | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 1.11e-2 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 5.00e-2 | 1.25e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 2.15e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 2.26e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-4 | 9.47e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 1.77e-2 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 8.36e-5 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 1.34e-6 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-3 | 1.09e-3 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 1.36e-4 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 2.23e-5 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 5.46e-6 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 4.08e-8 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 3.65e-6 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 1.42e-6 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 4.28e-8 |
Fetal stromal cell | Insulin Secretion | Insulin Secretion Rate | MTC | Wood | 2017 | NA | 527 | 5.00e-2 | 8.80e-3 |
Fetal stromal cell | Insulin Secretion | Insulin Secretion Rate | MTC | Wood | 2017 | NA | 527 | 1.00e-3 | 3.86e-2 |
Epithelial cell | Insulin Secretion | Insulin Secretion Rate | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 1.57e-2 |
Epithelial cell | Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 5.00e-2 | 3.93e-2 |
Epithelial cell | Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 1.39e-2 |
Fetal stromal cell | Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 5.00e-2 | 1.72e-2 |
Erythroid cell | Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 4.79e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 1.72e-2 |
Macrophage | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.76e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 3.44e-2 |
Fibroblast | Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 5.29e-3 |
Smooth muscle cell | Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 5.00e-2 | 2.01e-2 |
Smooth muscle cell | Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 1.00e-2 | 1.03e-2 |
Fibroblast | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 3.76e-2 |
Epithelial cell | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 3.76e-2 |
Epithelial cell | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-2 | 3.86e-2 |
Epithelial cell | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-3 | 3.21e-2 |
Fibroblast | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 3.86e-2 |
Smooth muscle cell | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-3 | 2.21e-2 |
Epithelial cell | Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 1.00e-2 | 2.44e-2 |
Epithelial cell | Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 1.00e-3 | 2.88e-2 |
Fibroblast | Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 5.00e-2 | 4.91e-2 |
Smooth muscle cell | Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.55e-2 |
Smooth muscle cell | Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 4.35e-2 |
Fibroblast | Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 5.00e-2 | 4.94e-2 |
Smooth muscle cell | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 2.19e-2 |
Smooth muscle cell | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-4 | 4.35e-2 |
Macrophage | Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 2.04e-2 |
Macrophage | Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 1.92e-2 |
Erythroid cell | Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 3.51e-3 |
Stromal cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 4.29e-2 |
Stromal cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 2.87e-3 |
Epithelial cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 4.35e-2 |
Smooth muscle cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 5.78e-4 |
Fibroblast | Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 5.00e-2 | 8.20e-3 |
Epithelial cell | Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 1.48e-2 |
Macrophage | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 9.03e-3 |
Macrophage | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 7.20e-4 |
Erythroid cell | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 3.13e-2 |
Erythroid cell | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 9.22e-3 |
Stromal cell | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 2.12e-3 |
Stromal cell | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 4.60e-2 |
Macrophage | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 3.66e-3 |
Macrophage | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 2.12e-2 |
Epithelial cell | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 1.05e-2 |
Epithelial cell | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-5 | 1.88e-2 |
Smooth muscle cell | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 2.28e-2 |
Smooth muscle cell | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 2.29e-2 |
Smooth muscle cell | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-4 | 9.42e-3 |
Macrophage | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 3.85e-2 |
Macrophage | Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 3.60e-2 |
Smooth muscle cell | Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 5.00e-2 | 1.26e-2 |
Erythroid cell | Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 1.00e-3 | 4.77e-2 |
Macrophage | Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 5.00e-2 | 2.27e-2 |
Stromal cell | Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 5.00e-2 | 1.71e-2 |
Macrophage | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.11e-3 |
Macrophage | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 3.20e-2 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.16e-5 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 5.25e-8 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.45e-12 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 9.33e-12 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 2.74e-10 |
Epithelial cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 4.37e-2 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.64e-5 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 3.37e-3 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 9.39e-4 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.64e-4 |
Macrophage | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.81e-3 |
Macrophage | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.67e-2 |
Stromal cell | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 3.26e-2 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 5.85e-5 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.29e-4 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.14e-8 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 6.00e-9 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 3.15e-9 |
Epithelial cell | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 3.15e-2 |
Epithelial cell | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 3.71e-2 |
Epithelial cell | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-3 | 2.88e-2 |
Stromal cell | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 8.54e-4 |
Fibroblast | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 1.88e-2 |
Epithelial cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 3.91e-2 |
Epithelial cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-3 | 3.88e-3 |
Epithelial cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-4 | 4.34e-4 |
Stromal cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 2.74e-2 |
Stromal cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 2.88e-2 |
Macrophage | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 2.60e-2 |
Erythroid cell | Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 3.39e-2 |
Fetal stromal cell | Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 8.63e-3 |
Erythroid cell | Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 2.67e-2 |
Smooth muscle cell | Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.81e-2 |
Smooth muscle cell | Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 2.90e-3 |
Erythroid cell | Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 7.09e-3 |
Fetal stromal cell | Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 4.13e-2 |
Fetal stromal cell | Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 4.98e-2 |
Epithelial cell | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 7.71e-3 |
Epithelial cell | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 3.09e-2 |
Erythroid cell | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 1.74e-2 |
Smooth muscle cell | Pubertal Anthropometrics | Late Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 4.98e-2 |
Fetal stromal cell | Pubertal Anthropometrics | Late Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 4.35e-2 |
Stromal cell | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 1.82e-2 |
Epithelial cell | Pubertal Anthropometrics | Total Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 1.51e-2 |
Stromal cell | Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 1.22e-2 |
Smooth muscle cell | Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 2.87e-3 |
Stromal cell | Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 8.31e-3 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 3.43e-7 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 1.42e-9 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 9.75e-12 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 2.83e-11 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 1.61e-12 |
Fetal stromal cell | Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-2 | 8.34e-3 |
Fetal stromal cell | Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-3 | 3.78e-3 |
Fetal stromal cell | Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-4 | 2.02e-2 |
Macrophage | Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 3.21e-2 |
Smooth muscle cell | Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-2 | 6.53e-3 |
Macrophage | Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 5.00e-2 | 1.43e-2 |
Smooth muscle cell | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 7.91e-3 |
Fetal stromal cell | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-2 | 1.86e-2 |
Epithelial cell | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 3.06e-2 |
Macrophage | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 2.74e-2 |
Macrophage | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 4.00e-3 |
Macrophage | Statin Efficacy | Delta HDL With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.68e-2 |
Fetal stromal cell | Statin Efficacy | Delta LDL With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.40e-2 |
Macrophage | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 3.59e-2 |
Macrophage | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 9.47e-3 |
Fetal stromal cell | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 2.11e-3 |
Epithelial cell | Tanner Stage | Tanner Stage All | MTC | Cousminer | 2014 | NA | 9913 | 5.00e-2 | 4.73e-2 |
Fetal stromal cell | Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 4.11e-2 |
Smooth muscle cell | Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 4.11e-2 |
Epithelial cell | Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-3 | 4.89e-2 |
Stromal cell | Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-3 | 4.89e-2 |
Stromal cell | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 2.52e-2 |
Smooth muscle cell | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 7.10e-3 |
Macrophage | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 9.03e-3 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-5 | 4.78e-2 |
Epithelial cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 4.79e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 3.45e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 4.50e-3 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 2.63e-3 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 5.76e-4 |
Fibroblast | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 3.10e-2 |
Fetal stromal cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 1.77e-2 |
Smooth muscle cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 3.17e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 3.18e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 1.36e-2 |
Fetal stromal cell | Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.89e-2 |
Fetal stromal cell | Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 4.00e-2 |
Fibroblast | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 7.98e-3 |
Fibroblast | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 8.65e-3 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.96e-2 |
Fibroblast | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 2.47e-2 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 9.55e-3 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 2.96e-2 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 2.04e-2 |
Fetal stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 7.49e-3 |
Fibroblast | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 9.66e-3 |
Fibroblast | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 1.16e-2 |
Fibroblast | Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 3.55e-2 |
Erythroid cell | BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-2 | 4.87e-2 |
Erythroid cell | BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-3 | 1.22e-2 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 1.42e-5 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 5.33e-8 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 9.45e-9 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 7.29e-9 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 9.06e-10 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 2.41e-2 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 3.04e-2 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 5.38e-4 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 5.70e-3 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 6.95e-3 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 4.46e-2 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 3.49e-2 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 8.32e-4 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 5.48e-4 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.59e-4 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 2.94e-5 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 3.97e-6 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 2.16e-6 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 1.18e-7 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 5.66e-7 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 3.85e-8 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 5.29e-9 |
Epithelial cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 3.19e-2 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 6.98e-8 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 1.19e-9 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 3.10e-14 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 3.77e-16 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 1.30e-16 |
Smooth muscle cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 3.90e-2 |
Smooth muscle cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 3.01e-2 |
Macrophage | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 4.05e-2 |
Macrophage | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-4 | 2.13e-2 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 9.34e-7 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 7.47e-11 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 2.15e-12 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 5.24e-9 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 2.57e-9 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 1.06e-5 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 3.42e-9 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.73e-10 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 1.18e-9 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 5.43e-11 |
Macrophage | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 1.51e-2 |
Macrophage | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 1.86e-3 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-3 | 2.79e-2 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 1.16e-2 |
Smooth muscle cell | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 4.89e-2 |
Fibroblast | Glycine level | Glycine levels, both male and female | ETC | Jia | 2019 | NA | 30118 | 5.00e-2 | 2.06e-2 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 2.15e-4 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 3.50e-5 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-3 | 9.46e-3 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 2.88e-2 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-5 | 4.35e-2 |
Macrophage | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 7.70e-3 |
Macrophage | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-2 | 3.84e-3 |
Macrophage | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-3 | 2.04e-3 |
Smooth muscle cell | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.49e-2 |
Smooth muscle cell | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.75e-2 |
Fibroblast | Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 4.59e-2 |
Smooth muscle cell | Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 4.59e-2 |
Smooth muscle cell | Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 3.40e-2 |
Fibroblast | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 3.61e-2 |
Fetal stromal cell | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.22e-2 |
Fetal stromal cell | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.18e-2 |
Fetal stromal cell | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-5 | 1.43e-2 |
Macrophage | Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 1.77e-2 |
Erythroid cell | Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 3.97e-2 |
Erythroid cell | Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 1.66e-2 |
Macrophage | Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 2.82e-3 |
Stromal cell | Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 1.83e-3 |
Stromal cell | Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 1.00e-2 | 1.08e-3 |
Fibroblast | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 1.51e-2 |
Fibroblast | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 5.58e-3 |
Macrophage | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 1.51e-2 |
Macrophage | Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 2.28e-2 |
Smooth muscle cell | Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 4.83e-2 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 5.73e-4 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 8.28e-4 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 1.28e-5 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 2.63e-7 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 8.06e-10 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 3.87e-4 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 3.01e-5 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 6.86e-8 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 2.79e-6 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 5.39e-8 |
Macrophage | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-2 | 1.91e-2 |
Stromal cell | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-3 | 4.53e-2 |
Stromal cell | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-4 | 1.27e-2 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 5.00e-2 | 2.47e-2 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-2 | 1.91e-2 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-3 | 5.16e-3 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-4 | 1.21e-3 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 1.67e-3 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 1.70e-2 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 4.45e-2 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 3.42e-3 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 3.27e-6 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 3.20e-5 |
Stromal cell | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 2.16e-2 |
Stromal cell | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 3.42e-3 |
Stromal cell | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 1.75e-2 |
Erythroid cell | MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 1.00e-2 | 4.10e-2 |
Epithelial cell | BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 5.00e-2 | 1.27e-2 |
Fibroblast | Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-2 | 3.07e-2 |
Fibroblast | Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-3 | 2.67e-2 |
Fibroblast | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 5.00e-2 | 1.33e-2 |
Erythroid cell | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 5.00e-2 | 2.60e-3 |
Stromal cell | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 1.00e-4 | 3.57e-2 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 1.40e-6 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 2.28e-6 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 3.08e-6 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 2.89e-6 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 2.05e-5 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 5.00e-2 | 3.37e-4 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 3.89e-5 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 6.13e-7 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 5.61e-7 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 4.73e-8 |
Stromal cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.10e-2 |
Fibroblast | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 2.21e-2 |
Fibroblast | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.55e-2 |
Fibroblast | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 4.14e-2 |
Stromal cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.18e-2 |
Stromal cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 3.11e-2 |
Macrophage | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 2.22e-2 |
Macrophage | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 4.26e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 5.00e-2 | 9.10e-3 |
Fibroblast | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-2 | 4.71e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-3 | 3.59e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 2.94e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 1.00e-2 | 2.77e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 1.00e-4 | 2.55e-2 |
Macrophage | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 3.45e-2 |
Erythroid cell | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 1.00e-2 | 2.87e-2 |
Smooth muscle cell | Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 6.98e-3 |
Smooth muscle cell | Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 9.22e-3 |
Smooth muscle cell | Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-5 | 1.76e-2 |
Macrophage | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-2 | 4.22e-2 |
Macrophage | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 4.63e-2 |
Macrophage | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-4 | 2.59e-2 |
Macrophage | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-5 | 4.80e-2 |
Erythroid cell | Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-4 | 4.93e-2 |
Erythroid cell | Positive affect | Positive affect | ETC | Baselmans | 2019 | NA | 410603 | 1.00e-4 | 3.09e-2 |
Fibroblast | Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 5.00e-2 | 1.02e-2 |
Fetal stromal cell | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 3.01e-2 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 9.23e-3 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 1.36e-2 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-3 | 5.68e-3 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 5.00e-2 | 4.35e-4 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-2 | 1.40e-3 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 2.18e-4 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 5.88e-6 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 1.03e-4 |
Epithelial cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-2 | 4.75e-2 |
Smooth muscle cell | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.10e-2 |
Fibroblast | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 3.87e-2 |
Fibroblast | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 4.79e-2 |
Macrophage | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.18e-2 |
Fibroblast | Hippocampal volume | Hippocampal tail volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.10e-2 |
Erythroid cell | Hippocampal volume | Hippocampal tail volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.57e-2 |
Stromal cell | Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.78e-2 |
Stromal cell | Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.19e-3 |
Stromal cell | Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 3.86e-2 |
Erythroid cell | Parasubiculum volume | Parasubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.33e-2 |
Fibroblast | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.07e-2 |
Macrophage | Brain volume | Dentate gyrus granule cell layer volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 3.21e-2 |
Fibroblast | Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.79e-2 |
Stromal cell | Subiculum volume | Subiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.61e-2 |
Fetal stromal cell | HATA volume | HATA volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.34e-2 |
Fetal stromal cell | HATA volume | HATA volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.86e-2 |
Stromal cell | Fimbria volume | Fimbria volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.01e-2 |
Stromal cell | Fimbria volume | Fimbria volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.78e-2 |
Fetal stromal cell | Fimbria volume | Fimbria volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.53e-2 |
Erythroid cell | Fimbria volume | Fimbria volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.01e-2 |
Fibroblast | Hippocampal volume | Hippocampal tail volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.09e-2 |
Stromal cell | Hippocampal volume | Hippocampal fissure volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 3.57e-2 |
Fibroblast | Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 1.54e-2 |
Epithelial cell | Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.99e-2 |
Fibroblast | HATA volume | Hippocampal amygdala transition area volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.46e-2 |
Fetal stromal cell | HATA volume | Hippocampal amygdala transition area volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.21e-2 |
Stromal cell | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 2.62e-2 |
Stromal cell | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 7.08e-4 |
Stromal cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 3.61e-2 |
Stromal cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 3.97e-2 |
Stromal cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 7.25e-3 |
Fetal stromal cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 3.61e-2 |
Smooth muscle cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 2.77e-2 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 1.17e-2 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 1.28e-3 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 8.91e-4 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 4.01e-3 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 9.39e-3 |
Macrophage | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 1.97e-3 |
Macrophage | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 7.74e-4 |
Macrophage | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 2.98e-2 |
Macrophage | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-4 | 4.80e-3 |
Macrophage | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-5 | 3.33e-3 |
Smooth muscle cell | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-4 | 1.52e-2 |
Epithelial cell | Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 1.00e-2 | 2.91e-2 |
Stromal cell | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-5 | 3.40e-2 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-2 | 3.52e-2 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-3 | 1.68e-3 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-4 | 1.65e-3 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 3.23e-4 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 5.00e-2 | 1.12e-6 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 5.55e-7 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 1.50e-6 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 2.55e-7 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 2.59e-7 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 2.58e-5 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.86e-8 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 5.29e-11 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 1.31e-10 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 3.34e-12 |
Smooth muscle cell | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 1.77e-2 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 9.63e-3 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-2 | 9.91e-4 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 1.63e-4 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 4.30e-2 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 1.16e-3 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 1.24e-3 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 7.09e-4 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 4.80e-4 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-3 | 8.85e-3 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-4 | 1.28e-2 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 1.56e-3 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 2.76e-2 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 9.11e-4 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 4.69e-5 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-4 | 1.63e-4 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-5 | 4.74e-5 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 3.29e-3 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 7.53e-3 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 3.46e-4 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 1.08e-6 |
Smooth muscle cell | Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 2.41e-2 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 3.93e-4 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 2.39e-6 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 9.68e-7 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 1.39e-6 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 2.87e-9 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 3.50e-3 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 2.46e-3 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 4.96e-6 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 5.46e-9 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 1.81e-9 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 5.48e-5 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 2.18e-5 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 3.35e-5 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 5.13e-5 |
Fibroblast | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 2.20e-3 |
Fibroblast | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 2.01e-2 |
Smooth muscle cell | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 7.17e-3 |
Stromal cell | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 3.21e-2 |
Fetal stromal cell | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-5 | 2.70e-2 |
Stromal cell | Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-2 | 2.99e-2 |
Macrophage | CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 5.00e-2 | 1.57e-3 |
Stromal cell | Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 4.15e-2 |
Epithelial cell | Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 4.65e-2 |
Macrophage | Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 5.00e-2 | 4.98e-2 |
Smooth muscle cell | Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-2 | 4.96e-2 |
Fibroblast | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.07e-2 |
Fibroblast | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 2.94e-2 |
Macrophage | Periodontal disease | Periodontal disease related phenotype (PCT3) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.03e-2 |
Epithelial cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.43e-2 |
Stromal cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.99e-2 |
Fetal stromal cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.38e-2 |
Epithelial cell | Periodontal disease | Periodontal disease related phenotype (PCT5) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 4.35e-2 |
Stromal cell | Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 3.47e-2 |
Smooth muscle cell | Nonalcoholic Liver disease | Liver fibrosis in non-alcoholic fatty acid liver disease | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.40e-2 |
Epithelial cell | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 2.58e-2 |
Macrophage | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.94e-2 |
Macrophage | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 1.00e-2 | 4.99e-2 |
Fibroblast | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 1.90e-2 |
Erythroid cell | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 3.93e-2 |
Macrophage | Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 1.09e-2 |
Smooth muscle cell | Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 1.00e-2 | 1.17e-2 |
Macrophage | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 2.20e-2 |
Stromal cell | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 2.23e-2 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-3 | 8.97e-3 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-4 | 1.72e-3 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 1.45e-2 |
Erythroid cell | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 1.45e-2 |
Epithelial cell | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 1.06e-2 |
Epithelial cell | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-4 | 5.71e-4 |
Fibroblast | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 3.03e-2 |
Fibroblast | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 4.26e-2 |
Fibroblast | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 7.41e-3 |
Fibroblast | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 2.58e-2 |
Erythroid cell | Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 3.90e-2 |
Stromal cell | Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 4.83e-2 |
Smooth muscle cell | Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.69e-2 |
Stromal cell | Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-4 | 1.05e-2 |
Stromal cell | Visceral adipose tissue | Predicted visceral adipose tissue Female | ETC | Karlsson T | 2019 | NA | 161,168 | 1.00e-5 | 2.84e-2 |
Epithelial cell | Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 5.00e-2 | 2.78e-2 |
Fetal stromal cell | Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 1.00e-2 | 4.81e-2 |
Fetal stromal cell | Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 1.00e-3 | 2.72e-2 |
Stromal cell | Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 3.96e-2 |
Smooth muscle cell | Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 1.85e-2 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 5.00e-2 | 2.18e-4 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-2 | 8.43e-5 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-3 | 3.84e-5 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 1.46e-5 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 1.76e-4 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 9.53e-6 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 1.85e-5 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 1.30e-4 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 6.99e-5 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 4.68e-3 |
Epithelial cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 4.49e-2 |
Epithelial cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 4.36e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 1.03e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 1.82e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 1.36e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-4 | 1.53e-3 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 3.89e-4 |
Fibroblast | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 3.95e-2 |
Fibroblast | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 4.36e-2 |
Fetal stromal cell | Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 5.00e-2 | 3.38e-2 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 8.87e-3 |
Fetal stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 4.02e-2 |
Macrophage | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 4.21e-2 |
Macrophage | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 9.07e-3 |
Macrophage | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 6.58e-4 |
Smooth muscle cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 4.87e-2 |
Fibroblast | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-3 | 4.21e-2 |
Fibroblast | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 3.43e-2 |
Macrophage | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-4 | 3.67e-2 |
Macrophage | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-5 | 2.23e-2 |
Fibroblast | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 2.77e-2 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 2.90e-4 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 1.08e-2 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 2.36e-2 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 5.00e-2 | 5.22e-3 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 4.58e-4 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 1.22e-4 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 5.68e-3 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-5 | 5.91e-3 |
Fetal stromal cell | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 4.10e-3 |
Macrophage | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-3 | 2.28e-2 |
Macrophage | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-4 | 4.83e-3 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-2 | 7.69e-3 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-3 | 2.76e-5 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 1.24e-5 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 9.02e-5 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 5.00e-2 | 1.71e-2 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-2 | 2.59e-4 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 1.19e-4 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-4 | 9.98e-3 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 8.17e-3 |
Erythroid cell | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-4 | 4.20e-2 |
Erythroid cell | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 4.59e-2 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 5.00e-2 | 1.48e-2 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-2 | 1.12e-3 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 3.89e-4 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 1.33e-3 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 3.29e-3 |
Macrophage | Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 5.00e-2 | 5.08e-3 |
Macrophage | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-2 | 3.98e-2 |
Macrophage | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-3 | 3.43e-2 |
Macrophage | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-4 | 2.21e-2 |
Epithelial cell | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 3.57e-2 |
Epithelial cell | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 1.00e-3 | 4.92e-2 |
Fetal stromal cell | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 1.00e-3 | 5.88e-3 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 2.72e-6 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 8.33e-9 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 2.81e-10 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 1.33e-9 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 1.81e-9 |
Smooth muscle cell | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 6.70e-3 |
Smooth muscle cell | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 5.85e-3 |
Fibroblast | Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 1.00e-3 | 4.89e-2 |
Macrophage | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 1.48e-2 |
Smooth muscle cell | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 1.83e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 6.20e-4 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 5.55e-8 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 1.48e-5 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 4.39e-8 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 1.06e-8 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 1.90e-4 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 1.91e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 1.30e-3 |
Epithelial cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 4.91e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 9.63e-5 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 9.38e-4 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 8.26e-6 |
Macrophage | BMI at birth | BMI at birth | ETC | Helgeland O | 2019 | NA | 9,286 | 5.00e-2 | 3.54e-2 |
Epithelial cell | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 5.00e-2 | 2.57e-2 |
Epithelial cell | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 2.56e-3 |
Macrophage | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 5.00e-2 | 2.57e-2 |
Macrophage | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 1.14e-2 |
Macrophage | BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 5.00e-2 | 2.05e-2 |
Macrophage | BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 1.00e-2 | 1.05e-2 |
Macrophage | BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 1.00e-3 | 2.13e-2 |
Fibroblast | BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 2.40e-2 |
Macrophage | BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 1.11e-2 |
Epithelial cell | BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 1.00e-4 | 3.86e-2 |
Erythroid cell | BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 3.82e-2 |
Fibroblast | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 2.73e-5 |
Fibroblast | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-2 | 9.87e-3 |
Stromal cell | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 5.00e-2 | 4.59e-2 |
Fetal stromal cell | BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 2.50e-2 |
Fetal stromal cell | BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 1.00e-2 | 1.83e-2 |
Stromal cell | BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 1.00e-2 | 1.83e-2 |
Macrophage | PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 1.00e-2 | 2.82e-2 |
Macrophage | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-2 | 2.32e-2 |
Macrophage | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-3 | 3.06e-4 |
Erythroid cell | Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 8.05e-3 |
Fibroblast | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 1.43e-2 |
Fibroblast | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 1.17e-2 |
Fetal stromal cell | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 3.79e-2 |
Fetal stromal cell | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 1.17e-2 |
Fetal stromal cell | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 2.15e-3 |
Fetal stromal cell | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-4 | 5.56e-3 |
Fetal stromal cell | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-5 | 2.28e-2 |
Stromal cell | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 2.97e-2 |
Stromal cell | Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-2 | 4.49e-2 |
Epithelial cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 2.31e-2 |
Fetal stromal cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 3.73e-4 |
Fetal stromal cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 1.47e-2 |
Fetal stromal cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-5 | 3.98e-2 |
Smooth muscle cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 3.49e-2 |
Smooth muscle cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-5 | 1.40e-2 |
Fibroblast | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 3.64e-2 |
Fibroblast | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 1.63e-3 |
Fibroblast | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 2.21e-2 |
Smooth muscle cell | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 4.88e-2 |
Erythroid cell | Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 1.13e-2 |
Macrophage | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-5 | 2.24e-2 |
Macrophage | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 5.00e-2 | 2.37e-2 |
Fibroblast | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.04e-2 |
Erythroid cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.32e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.80e-3 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.23e-3 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.41e-2 |
Fibroblast | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.44e-2 |
Fibroblast | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.19e-3 |
Smooth muscle cell | IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.45e-2 |
Stromal cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.29e-2 |
Stromal cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.18e-2 |
Smooth muscle cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.64e-2 |
Smooth muscle cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.51e-2 |
Stromal cell | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 5.00e-2 | 4.60e-2 |
Macrophage | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-2 | 1.11e-2 |
Macrophage | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-3 | 1.82e-2 |
Macrophage | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-4 | 1.57e-3 |
Macrophage | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-5 | 8.02e-3 |
Stromal cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-4 | 3.29e-2 |
Smooth muscle cell | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 4.32e-2 |
Smooth muscle cell | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-2 | 3.78e-2 |
Macrophage | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 2.87e-2 |
Macrophage | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-3 | 3.98e-3 |
Erythroid cell | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 1.86e-2 |
Erythroid cell | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-2 | 1.75e-2 |
Fibroblast | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 3.30e-2 |
Fibroblast | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 3.62e-2 |
Fibroblast | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 7.75e-3 |
Fibroblast | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 4.16e-2 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 3.13e-4 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 9.93e-5 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 1.66e-3 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 1.34e-2 |
Smooth muscle cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-3 | 4.59e-2 |
Smooth muscle cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-4 | 1.66e-2 |
Smooth muscle cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-5 | 1.37e-2 |
Fetal stromal cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 1.71e-2 |
Fibroblast | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-2 | 2.91e-3 |
Fibroblast | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 2.30e-2 |
Erythroid cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 1.45e-2 |
Epithelial cell | COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-2 | 1.48e-2 |
Fibroblast | COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 4.71e-2 |
Fetal stromal cell | COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 4.71e-2 |
Stromal cell | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-3 | 4.89e-2 |
Smooth muscle cell | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 1.00e-2 | 1.65e-2 |
Smooth muscle cell | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 1.00e-3 | 2.28e-2 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 5.00e-2 | 3.92e-4 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-2 | 8.97e-3 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-3 | 1.47e-4 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 1.73e-5 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 4.00e-5 |
Macrophage | COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 5.00e-2 | 1.56e-3 |
Macrophage | COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 2.43e-2 |
Fibroblast | COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-3 | 9.32e-3 |
Stromal cell | COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 5.00e-2 | 2.76e-2 |
Fibroblast | COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 1.00e-2 | 3.82e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.